GHK-Cu peptide dosage chart: Where Numbers Come From

The ghk-cu peptide dosage chart below shows what the numbers really are: doses commonly reported in the community, not clinically validated doses. No human dose-ranging trial has established an injectable GHK-Cu dose; the familiar 0.5–3 mg figures come from repeated clinic sheets, vendor charts, and forum convention, not a clinical program.

What does a GHK-Cu dosage chart actually show?

A GHK-Cu dosage chart shows a market convention, not a dose selected by human efficacy and safety trials. The useful version labels each figure by evidence tier. That keeps a frequently copied number from acquiring a white coat merely because it appears in a tidy table.

Commonly reported figure	Where the figure sits online	What the evidence supports
0.5 mg per injection	Usually labeled “low,” “starter,” or “sensitive”	Community-reported; no validated starting dose
1–2 mg per injection	The center of most injectable charts and clinic sheets	Community-reported; no human dose-ranging basis
3 mg per injection	Often presented as an upper chart value	Community-reported; no established maximum effective dose
Daily, 2–3 times weekly, or 5 days weekly	Schedules vary between otherwise similar charts	Community-reported; no schedule has been clinically compared
4–12 week cycles	Repeated as a cycle length across guides	Community-reported; no human trial has validated cycling

These are doses commonly reported in the community, not clinically validated. They are not a personal protocol, and the table does not identify an effective or safe amount for an individual.

Where did the injectable numbers come from?

The injectable numbers appear to come from repetition across peptide vendors, clinic handouts, calculators, and community posts rather than one traceable clinical study. A live review of the leading non-Reddit results on July 16, 2026 found the same small set of milligram amounts paired with conflicting frequencies and cycle lengths. The citation trail usually led to general GHK-Cu biology, not to the dose in the chart.

Searches for a ghk cu peptide injection dosage chart or a ghk-cu peptide injection dosage chart pdf tend to return arithmetic with the scientific step missing. One page calls 1 mg a baseline; another calls 2 mg standard; another stretches the range to 3 mg or beyond. None of the primary sources opened for this review tested those isolated subcutaneous doses against one another.

The copied pattern matters. Agreement between unsourced charts can show what a community commonly reports. Agreement cannot establish absorption, dose response, long-term safety, or the point where more GHK-Cu stops helping.

Has injectable GHK-Cu been studied in humans?

Injectable copper tripeptide-1 has appeared in a human study, but not in a way that validates the familiar GHK-Cu schedule. A 2018 open-label study gave intradermal scalp injections to 1,000 people every three weeks, but the product combined copper tripeptide-1 with several growth factors and thymosin beta-4. The study did not isolate GHK-Cu or compare GHK-Cu doses.

That distinction is the hinge. The published hair-formulation study is human injection evidence for a mixture and a specific intradermal procedure. It is not evidence for 0.5, 1, 2, or 3 mg of GHK-Cu injected subcutaneously. A mixture study cannot quietly become a single-ingredient ghk-cu peptide dosage study after passing through a PDF.

PubMed and ClinicalTrials.gov searches found no human trial that ranged isolated injectable GHK-Cu doses to establish efficacy, pharmacokinetics, tolerability, or a maximum dose. That is why the honest cell in a clinical ghk peptide dosage table remains “not established.”

What doses have clinical researchers actually specified?

Clinical researchers have specified topical GHK-Cu amounts, not a validated systemic injection dose. The current Phase 2 wound study uses a 0.1% weight/weight topical gel, applies about 0.5 g once daily, and runs for 14 days. The trial is registered and has no posted results yet, so even that number is a test condition rather than an approved dose.

The ClinicalTrials.gov record is useful because it keeps route, concentration, amount, frequency, duration, and purpose attached. Online charts often detach one number and let readers assume it belongs everywhere.

Topical percentages cannot be converted into injectable milligrams by simple proportion. Skin acts as a barrier and reservoir; a subcutaneous injection bypasses that barrier. The GHK-Cu profile separates the modest human topical evidence from the much thinner systemic evidence.

What does the FDA say in 2026?

The FDA has not established an approved injectable GHK-Cu dose, and its current compounding material draws a route-specific line. FDA says compounded injectable GHK-Cu may pose immunogenicity risks from aggregation and peptide-related impurities, while human data are limited. “Immunogenicity” means the product may provoke an unwanted immune response.

The FDA safety-risk page lists injectable GHK-Cu among withdrawn nominations. FDA’s May 14, 2026 503A document places GHK-Cu except injectable routes in Category 1, under evaluation, after the nominator clarified that the injectable nomination was withdrawn. Category 1 is not approval, and neither document supplies a dose.

This regulatory detail also undercuts pages that describe compounded availability as clinical validation. A pharmacy preparation and an FDA-reviewed dosing label are different things.

How should reconstitution math be kept separate from dose selection?

Reconstitution math can convert a chosen mass into liquid volume; it cannot choose or validate the mass. If a 2 mg line appears in a chart, changing vial size or water volume changes the syringe-unit reading but does not make 2 mg evidence-based. Arithmetic answers “how much liquid contains this mass?” Science must answer “why this mass?”

The guide to how to reconstitute a peptide explains concentration and unit conversion without pretending to select a dose. The broader peptide dosing chart also separates FDA-labeled doses, human research doses, and compounds with no established human schedule.

For GHK-Cu, the bottom line stays plain: 0.5–3 mg figures describe community practice, not a clinically validated injection range. A real ghk-cu peptide dosage chart should preserve that label until an isolated human dose-ranging trial supplies something better.